© Springer International Publishing AG 2017Daniel C. Baumgart (ed.)Crohn’s Disease and Ulcerative Colitis10.1007/978-3-319-33703-6_42 42. Biologic Therapy in Moderate-to-Severe Ulcerative Colitis: Infliximab Mindy Lam1 and Brian Bressler1 (1) Division of Gastroenterology, University of British Columbia, Vancouver, BC,…
Study Corticosteroid (starting dose) Comparator No. of patients Disease extent Duration (weeks) End-points Remission NNT (95 % CI) Intravenous Meyers [6] 1983 Hydrocortisone (300 mg daily) Corticotropin (ACTH) 120 U/day…
Fig. 31.1 Methotrexate (MTX) metabolism . MTX and its polyglutamate metabolites (MTXPG) potently inhibit dihydrofolate reductase (DHFR), impairing the conversion of dihydrofolate (FH2) to tetrahydrofolate (FH4). MTXPG also inhibit folate-dependent…
© Springer International Publishing AG 2017Daniel C. Baumgart (ed.)Crohn’s Disease and Ulcerative Colitis10.1007/978-3-319-33703-6_29 29. Steroid Therapy for Crohn’s Disease A. Hillary Steinhart1 (1) IBD Centre, Mount Sinai Hospital and Department of Medicine, University of Toronto, Room…
© Springer International Publishing AG 2017Daniel C. Baumgart (ed.)Crohn’s Disease and Ulcerative Colitis10.1007/978-3-319-33703-6_28 28. Conventional Medical Management of Crohn’s Disease: Sulfasalazine Miquel A. Gassull1, 2 and Eduard Cabré3, 4 (1) Health Science Research Institute, Germans Trias i…
1. Approximately one third of patients has chronically active disease or fluctuating disease and hence this is the cohort most likely to be treated by more aggressive immunomodulating therapy. However,…
Fig. 25.1 Conceptual model of variables influencing quality of life in inflammatory bowel disease (reprinted from ref. [16] with permission from John Wiley & Sons, Inc.) While most studies of…
Stool frequency a 0: Normal 1: Number of stools for this patient 1–2 stools more than normal 2: 3–4 stools more than normal 3: 5 or more stools more than…
© Springer International Publishing AG 2017Daniel C. Baumgart (ed.)Crohn’s Disease and Ulcerative Colitis10.1007/978-3-319-33703-6_21 21. Laboratory Evaluation, Including Novel Diagnostic Markers M. Flamant1 and X. Roblin2 (1) Institut des Maladies de l’Appareil Digestif (IMAD), Hotel Dieu, CHU…
Fig. 16.1 Overview of Intestinal Organoid systems . Intestinal organoids can be derived by a variety of methods. Intestinal crypts and LGR5-expressing stem cells can be isolated from IBD patient…
